San Francisco, CA, United States of America

Thomas Harding

USPTO Granted Patents = 10 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 38(Granted Patents)

Company Filing History:

6 out of 71

Five Prime Therapeutics, Inc.

Biosante Pharmaceuticals, Inc.

patents

Years Active: 2007-2022

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11235059 - Afucosylated anti-FGFR2IIIB antibodies (2022-02-01),

2. 10537611 - Methods of treating lung cancer (2020-01-21),

3. 10172937 - Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies (2019-01-08),

4. 10016484 - Methods of treating lung cancer (2018-07-10),

5. 9669081 - Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer (2017-06-06),

6. 9169313 - Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins (2015-10-27),

7. 8840881 - Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer (2014-09-23),

8. 8614183 - Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 (2013-12-24),

9. 7939271 - Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer (2011-05-10),

10. 7186699 - Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes (2007-03-06),

Title: Thomas Harding: Innovator in Cancer Treatment

Introduction

Thomas Harding is a prominent inventor based in San Francisco, CA (US). He has made significant contributions to the field of cancer treatment, holding a total of 10 patents. His work focuses on innovative therapies that target specific cancer-related proteins.

Latest Patents

Among his latest patents, Harding has developed afucosylated anti-FGFR2IIIB antibodies. This invention provides antibodies that bind to FGFR2IIIb, with at least 95% of the antibodies in the composition being afucosylated. Additionally, he has created methods for treating cancers that involve FGFR1 gene amplification. These methods include administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain and/or an FGFR1 ECD fusion molecule, often in combination with other therapeutic agents.

Career Highlights

Throughout his career, Thomas Harding has worked with notable companies such as Five Prime Therapeutics, Inc. and Aduro Gvax Inc. His innovative approaches have positioned him as a key player in the development of new cancer therapies.

Collaborations

Harding has collaborated with esteemed colleagues, including Karin Ute Jooss and Minh Nguyen. These partnerships have further enhanced his research and development efforts in the field of oncology.

Conclusion

Thomas Harding's contributions to cancer treatment through his patents and collaborations highlight his role as a leading inventor in the medical field. His innovative work continues to pave the way for advancements in cancer therapies.

This text is generated by artificial intelligence and may not be accurate.